Vi­su­al­ize: AS­CO 2018's win­ners and losers

On­col­o­gy’s biggest year­ly event wrapped up in Chica­go ear­li­er this week, where our ed­i­tor-in-chief John Car­roll brought you cov­er­age on the biggest boons and blun­ders for AS­CO pre­sen­ters.

There was the wide­ly-cov­ered Nek­tar im­plo­sion, in which the com­pa­ny fum­bled the pre­sen­ta­tion of da­ta on NK­TR-214 — spook­ing in­vestors and tank­ing the com­pa­ny’s stock as low as 42% in the days af­ter. Then Roche dumped its PhI­II PI3K ef­fort on taselis­ib, and its Tecen­triq/chemo com­bo came up short in com­par­i­son to ri­vals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.